Literature DB >> 1527789

Antitumor imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC.

P R Lowe1, C E Sansom, C H Schwalbe, M F Stevens, A S Clark.   

Abstract

The antitumor imidazotetrazinone, temozolomide (5), C6H6N6O2, forms crystals with unit cell dimensions a = 17.332 (3), b = 7.351 (2), c = 13.247 (1), beta = 109.56 (1) degree and space group P21/c. A doubly hydrogen-bonded dimer constitutes the asymmetric unit. One carboxamide group forms an additional intermolecular NH...O hydrogen bond; in both molecules the carboxamide group is coplanar with the heterocycle and its NH2 group interacts with the imidazole nitrogen atom N(7). Molecular orbital calculations show the carbonyl carbon C(4) to be the most electron deficient atom, with relatively weak N(3)-C(4) and C(4)-N(5) bonds confirming that temozolomide should ring-open at this position in solution. The energy barrier to carboxamide group rotation of approximately 20 kJ mol-1 should permit interconversion between rotamers. In temozolomide and the related drug mitozolomide (4), N(7) is more negatively charged than N(1), which favors the formation of hydrogen bonds to the former atom in spite of their poor geometry. The relevance of these structural features to the action of temozolomide as a major-groove-directed prodrug of the alkylating agent MTIC (3) is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527789     DOI: 10.1021/jm00096a013

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  The simulation of UV spectroscopy and electronic analysis of temozolomide and dacarbazine chemical decomposition to their metabolites.

Authors:  M Hossein Khalilian; Saber Mirzaei; Avat Arman Taherpour
Journal:  J Mol Model       Date:  2016-10-25       Impact factor: 1.810

2.  Hydrogen bonded and stacked geometries of the temozolomide dimer.

Authors:  Okuma Emile Kasende; Jules Tshishimbi Muya; Vincent de Paul N Nziko; Steve Scheiner
Journal:  J Mol Model       Date:  2016-03-14       Impact factor: 1.810

3.  Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro.

Authors:  B J Jean-Claude; A Mustafa; N D Cetateanu; Z Damian; J De Marte; R Yen; D Vasilescu; T H Chan; B Leyland-Jones
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Synthesis and Molecular-cellular Mechanistic Study of Pyridine Derivative of Dacarbazine.

Authors:  Marzieh Amirmostofian; Jalal Pourahmad Jaktaji; Zohreh Soleimani; Kimia Tabib; Farahnaz Tanbakosazan; Mirdavood Omrani; Farzad Kobarfard
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

5.  Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.

Authors:  Nausicaa Clemente; Benedetta Ferrara; Casimiro Luca Gigliotti; Elena Boggio; Maria Teresa Capucchio; Elena Biasibetti; Davide Schiffer; Marta Mellai; Laura Annovazzi; Luigi Cangemi; Elisabetta Muntoni; Gianluca Miglio; Umberto Dianzani; Luigi Battaglia; Chiara Dianzani
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

6.  Identification and physicochemical characteristics of temozolomide process-related impurities.

Authors:  Marta Łaszcz; Marek Kubiszewski; Lukasz Jedynak; Monika Kaczmarska; Łukasz Kaczmarek; Wojciech Łuniewski; Krzysztof Gabarski; Anna Witkowska; Krzysztof Kuziak; Maura Malińska
Journal:  Molecules       Date:  2013-12-11       Impact factor: 4.411

7.  Synthesis and growth-inhibitory activities of imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position.

Authors:  David Cousin; Marc G Hummersone; Tracey D Bradshaw; Jihong Zhang; Christopher J Moody; Magdalena B Foreiter; Helen S Summers; William Lewis; Richard T Wheelhouse; Malcolm F G Stevens
Journal:  Medchemcomm       Date:  2018-01-19       Impact factor: 3.597

8.  The medicinal chemistry of imidazotetrazine prodrugs.

Authors:  Catherine L Moody; Richard T Wheelhouse
Journal:  Pharmaceuticals (Basel)       Date:  2014-07-10

9.  Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma.

Authors:  Riley L Svec; Lucia Furiassi; Christine G Skibinski; Timothy M Fan; Gregory J Riggins; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2018-11-08       Impact factor: 5.100

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.